Publicado
Estudio molecular de la inversión de los intrones 1 y 22 del factor VIII de la coagulación en niños con hemofilia A severa utilizando técnica de PCR de larga distancia
Molecular study in children with hemophilia A in Colombia: analysis of Intron 1 and 22 inversion using long-distance PCR technique
DOI:
https://doi.org/10.15446/revfacmed.v65n2.57012Palabras clave:
Hemofilia A, Factor VIII, Intrón. (es)Hemophilia A, Factor VIII, Introns. (en)
Introducción. La hemofilia A es una enfermedad recesiva ligada al cromosoma X, con una incidencia de 1 en 5 000 a 10 000 varones y es el trastorno hemostático congénito más frecuente en varones. En pacientes con fenotipo severo, las inversiones de los intrones 22 y 1 son las mutaciones más comunes con una prevalencia del 45% a 50% y del 1% al 5% de los pacientes, respectivamente.
Objetivo. Determinar la frecuencia de la inversión de los intrones 1 y 22 del gen del factor VIII de la coagulación en menores de 18 años con hemofilia A severa en Bogotá D.C.
Materiales y métodos. Estudio descriptivo y transversal. La identificación de la inversión de los intrones 1 y 22 del gen del factor VIII se realizó mediante técnicas de reacción en cadena de polimerasa de larga distancia.
Resultados. Se estudiaron 30 pacientes y se encontró inversión del intrón 22 en 12 pacientes (40%) e inversión 1 en 3 pacientes, cifras similares a las observadas en otros estudios.
Conclusiones. Se encontraron las inversiones de los intrones 1 y 22 en la mitad de los pacientes evaluados. Los resultados son reproducibles, por lo que constituyen una herramienta útil para la identificación de las dos mutaciones más frecuentes en hemofilia A severa.
Introduction: Hemophilia A is an X-linked recessive disease with an incidence of 1 in 5 000 to 10 000 males. It is the most common congenital hemostatic disorder in men. The inversion of introns 1 and 22 in patients with a severe phenotype is considered the most frequent abnormality, with a prevalence of 1 to 5% and 45 to 50%, respectively.
Objective: To determine the frequency of introns 1 and 22 inversions in factor VIII gene in children under 18 years with severe hemophilia A in Bogotá.
Materials and methods: This is a non-experimental, descriptive, transverse study. The inversions of introns 1 and 22 for factor VIII gene were identified using long-distance polymerase chain reaction techniques in pediatric patients with severe Hemophilia A treated in different centers of Bogotá, Colombia.
Results: Thirty patients were analyzed. Inversion of intron 22 was found in 12 patients (40%), while inversion of intron 1 was observed in 3 patients. These findings are similar to other studies.
Conclusions: Inversions of intron 22 and 1 were found in half of this group of patients. These results are reproducible and useful to identify the two most frequent mutations in severe hemophilia A patients.
Referencias
Graw J, Brackmann HH, Oldenburg J, Schneppenheim R, Spannagl M, Schwaab R. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet. 2005;6(6):488-501. http://doi.org/cxfj5s.
Oldenburg J, Pezeshkpoor B, Pavlova A. Historical review on genetic analysis in hemophilia A. Semin Thromb Hemost. 2014;40(8):895-902. http://doi.org/f6r9m2.
Leiria LB, Roisenberg I, Salzano FM, Bandinelli E. Introns 1 and 22 inversions and factor VIII inhibitors in patients with severe haemophilia A in southern Brazil. Haemophilia. 2009;15(1):309-13. http://doi.org/dtgq3g.
Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121(20):4046-55. http://doi.org/f24kcr.
Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368(3):231-9. http://doi.org/f23jqd.
Royal Postgraduate Medical School. Haemophilia A Mutation Search Test and Resource Site (HAMSTeRS). London: Hammersmith Hospital; 2016 [cited 2016 Mar 23]. Available from: http://goo.gl/50NbII.
Cuenta de Alto Costo, Fondo Colombiano de Enfermedades de Alto Costo. Situación de la hemofilia en Colombia. 2015. Bogotá D.C: Cuenta de Alto Costo; 2015.
Albánez S, Ruiz-Sáez A, Boadas A, de Bosch N, Porco A. Identification of factor VIII gene mutations in patients with severe haemophilia A in Venezuela: identification of seven novel mutations. Haemophilia. 2011;17(5):e913-8. http://doi.org/bj8dbg.
Reitter S, Sturn R, Horvath B, Freitag R, Male C, Muntean W, et al. Spectrum of causative mutations in patients with haemophilia A in Austria. Thromb Haemost. 2010;104(1):78-85. http://doi.org/fvcbtx.
Bagnall RD, Waseem N, Green PM, Giannelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood. 2002;99(1):168-74. http://doi.org/cmbq47.
Liu Q, Nozari G, Sommer SS. Single-tube polymerase chain reaction for rapid diagnosis of the inversion hotspot of mutation in hemophilia A. Blood. 1998; 92(4):1458-9.
Goodeve A. Molecular genetic testing of hemophilia A. Semin Thromb Hemost. 2008;34(6):491-501. http://doi.org/b2p5gd.
Poláková H, Zmetáková I, Kádasi L. Long distance PCR in detection of inversion mutations of F8C gene in hemophilia A patients. Gen Physiol Biophys. 2003;22(2):243-53.
Asociación Médica Mundial. Declaración de Helsinki de la Asociación Médica Mundial. Principios éticos para las investigaciones médica en seres humanos. Fortaleza: 64a Asamblea General de la AMM; 2013 [cited 2017 Jun 6] Available from: http://goo.gl/ SSm0WS.
Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, et al. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia. 2012;18(3):375-82. http://doi.org/cgk4wr.
Mantilla-Capacho JM, Beltrán-Miranda CP, Luna-Záizar H, Aguilar-López L, Esparza-Flores MA, López-Guido B, et al. Frequency of intron 1 and 22 inversions of Factor VIII gene in Mexican patients with severe hemophilia A. Am J Hematol. 2007;82(4):283-7. http://doi.org/b3shcv.
Margaglione M, Castaman G, Morfini M, Rocino A, Santagostino E, Tagariello G, et al. The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica. 2008;93(5):722-8. http://doi.org/cnsxt9.
Casaña P, Cabrera N, Cid AR, Haya S, Beneyto M, Espinós C, et al. Severe and moderate hemophilia A: identification of 38 new genetic alterations. Haematologica. 2008;93(7):1091-4. http://doi.org/b5qmdg.
Rossetti LC, Szurkalo I, Radic CP, Abelleyro MM, Primiani L, Neme D, et al. Factor VIII genotype characterization of haemophilia A affected patients with transient and permanent inhibitors: a comprehensive Argentine study of inhibitor risks. Haemophilia. 2013;19(4):511-8. http://doi.org/f423jr.
Rossetti LC, Candela M, Bianco RP, de Tezanos-Pinto M, Western A, Goodeve A, et al. Analysis of factor VIII gene intron 1 inversion in Argentinian families with severe haemophilia A and a review of the literature. Blood Coagul Fibrinolysis. 2004;15(7):569-72. http://doi.org/cxr4q9.
Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia. 2006;12(Suppl 6):15-22. http://doi.org/djzkgt.
Gouw SC, van den Berg HM, Oldenburg J, Astermark J, de Groot PG, Margaglione M, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012;119(12):2922-34. http://doi.org/fzrzzt.
Hashemi SM, Fischer K, Moons KG, van der Berg HM. Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A. Haemophilia. 2015;21(2):227-33. http://doi.org/f626gv.
Schröder J, El-Maarri O, Schwaab R, Müller CR, Oldenburg J. Factor VIII intron-1 inversion: frequency and inhibitor prevalence. J Thromb Haemost. 2006;4(5):1141-3. http://doi.org/fc3t6d.
Bernal-Villegas J, Suárez-Obando F. La carga de la enfermedad genética en Colombia, 1996-2025. Univ. Méd. Bogotá. 2008;49(1):12-28.
Dimensions
PlumX
Visitas a la página del resumen del artículo
Descargas
Cómo citar
Licencia
Derechos de autor 2017 Revista de la Facultad de Medicina
Esta obra está bajo una licencia Creative Commons Reconocimiento 3.0 Unported.
-
